What GLP-1 medications are
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after eating to signal fullness, slow digestion, and regulate blood sugar. GLP-1 receptor agonists are drugs that mimic and amplify this signal, producing effects that go well beyond willpower.
The two medications currently approved for chronic weight management in adults are:
Semaglutide
- Weekly subcutaneous injection
- ~15% average body weight loss in trials
- FDA-approved for chronic weight management
- Reduces cardiovascular risk (SURPASS-CVOT data)
- Widely covered by insurance for eligible patients
Tirzepatide
- Weekly subcutaneous injection
- ~20–22% average body weight loss in trials
- Activates both GLP-1 and GIP receptors
- Strongest metabolic effects currently available
- Covered by many commercial insurance plans
Why these numbers matter: Prior to GLP-1 medications, the most effective non-surgical weight loss intervention (intensive lifestyle modification) produced 5–10% weight loss on average. Tirzepatide's 20–22% average approaches the outcomes of bariatric surgery — without the procedure.
Both medications work primarily through appetite suppression and delayed gastric emptying. You feel full sooner, stay full longer, and experience dramatically reduced food noise — the constant mental preoccupation with eating that makes traditional dieting so difficult to sustain.
Medical weight loss vs. dieting
Persistent weight gain — especially in middle age and beyond — is rarely a discipline problem. It's a metabolic problem. For many patients, multiple overlapping factors are working against them simultaneously:
- Insulin resistance — cells stop responding to insulin normally, driving fat storage and hunger
- Hormonal disruption — low testosterone, elevated cortisol, or thyroid dysfunction impairs metabolism
- Leptin resistance — the satiety hormone stops working, so the body never gets the "full" signal
- Inflammation — chronic low-grade inflammation interferes with metabolic signaling
- Gut microbiome dysbiosis — altered gut bacteria extract more calories and influence appetite
Dieting addresses behavior. Medical weight loss addresses biology. Telling someone with significant insulin resistance and thyroid dysfunction to "eat less and move more" is like telling someone with a broken arm to type faster. The underlying biology has to be addressed, or the behavior change won't stick.
| Dieting / Lifestyle Only | Medical Weight Loss (GLP-1) | |
|---|---|---|
| Average weight loss | 3–8% of body weight | 15–22% of body weight |
| Mechanism | Caloric restriction + behavior | Appetite regulation + metabolic reset |
| Hunger management | Relies entirely on willpower | Neurologically reduces food cravings |
| Long-term sustainability | ~5% maintain results at 5 years | Strong results maintained during treatment |
| Cardiovascular benefit | Indirect, through weight loss | Direct — GLP-1 receptors in the heart |
| Medical supervision | Not required | Required — labs, monitoring, dosing |
The critical word in "medical weight loss" is medical. GLP-1 medications require a licensed prescriber, baseline lab work, and ongoing monitoring. This isn't a wellness supplement — it's a pharmaceutical intervention with real efficacy and real considerations. That's why the prescription-only model exists, and why telehealth programs that skip the clinical evaluation create risk.
Dr. Morris's approach: labs + GLP-1 + coaching
Most telehealth GLP-1 providers offer a quick questionnaire, a prescription, and a monthly refill. Dr. Morris's approach is different — because weight gain has metabolic causes that a prescription alone doesn't address.
Step 1: Comprehensive metabolic labs before anything else
Before writing a prescription, Dr. Morris orders a full metabolic workup. Not a basic panel — a functional medicine panel designed to identify the specific drivers of your weight resistance. This typically includes:
- Fasting insulin and HOMA-IR (insulin resistance index)
- Full thyroid panel — TSH, Free T3, Free T4, reverse T3, thyroid antibodies
- Comprehensive metabolic panel — liver, kidney, glucose
- Sex hormones — testosterone, estradiol, SHBG, DHEA-S
- Inflammatory markers — hsCRP, homocysteine
- Lipid panel with particle sizing where indicated
- Cortisol and adrenal function (DUTCH panel when appropriate)
Why this matters: A patient with undiagnosed hypothyroidism and insulin resistance won't get full benefit from GLP-1 therapy unless those issues are addressed in parallel. Finding and correcting these factors before or alongside GLP-1 treatment produces significantly better results than medication alone.
Step 2: GLP-1 therapy with proper dose escalation
Once labs are reviewed and eligibility confirmed, Dr. Morris prescribes semaglutide or tirzepatide with a structured dose-escalation schedule. This minimizes side effects during the adjustment period and ensures you reach a therapeutic dose safely. Prescriptions are sent to a pharmacy of your choice — including mail-order options for convenience.
Step 3: Functional medicine coaching alongside the medication
GLP-1 medications suppress appetite, but they don't teach your body how to use the window of opportunity well. Dr. Morris's program includes functional medicine coaching covering:
- Protein prioritization — preserving muscle mass during rapid weight loss
- Gut health support — managing GI side effects and supporting the microbiome
- Metabolic optimization — correcting any thyroid, hormone, or insulin resistance issues found in labs
- Nutrition patterns — evidence-based approaches that work with GLP-1 biology, not against it
- Sleep and stress management — cortisol control directly impacts fat distribution and hunger
Step 4: Ongoing monitoring and lab review
Dr. Morris monitors liver and kidney function, thyroid markers, and metabolic panels throughout your program. Dosing is adjusted based on your response and lab results — not a one-size protocol. Most patients benefit from check-ins every 6–8 weeks during active treatment.
Who qualifies for GLP-1 therapy
FDA approval guidelines for GLP-1 weight loss medications specify the following eligibility criteria:
BMI 30 or higher
Adults with a body mass index of 30+ qualify without requiring a comorbid condition.
BMI 27+ with comorbidity
Adults with BMI 27–29.9 qualify with at least one weight-related condition: type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea.
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. Active pancreatitis. Severe GI disease. Pregnancy or breastfeeding.
Medical evaluation required
Eligibility is confirmed through a virtual consultation + lab work. Some conditions require additional evaluation before prescribing.
If you're unsure whether you qualify, the free initial consultation is the right next step. Dr. Morris reviews your health history, current medications, and any contraindications before recommending a path forward.
What to expect: consultation to prescription
The process is entirely virtual — no office visits, no travel. Here's how it works from first contact to active treatment:
Free virtual consultation
A 20-minute video call with Dr. Morris. You discuss your health history, symptoms, prior weight loss attempts, current medications, and goals. Dr. Morris assesses whether GLP-1 therapy is appropriate and explains the full protocol.
Baseline lab panel
You receive a lab order for a comprehensive metabolic workup. Labs can be completed at a local lab (LabCorp, Quest) or via at-home kit depending on your location. Results are typically available within 3–5 business days.
Lab review consultation
Dr. Morris reviews your results with you via a second video visit. He identifies any metabolic, hormonal, or thyroid issues to address, confirms GLP-1 eligibility, and determines whether semaglutide or tirzepatide is the better fit for your profile.
Prescription + dose escalation schedule
Your prescription is sent to a pharmacy of your choice. Dr. Morris provides a dose-escalation schedule calibrated to minimize side effects. You start at the lowest dose and titrate up over 16–20 weeks to a therapeutic maintenance dose.
Ongoing monitoring and coaching
Check-ins every 6–8 weeks during active treatment. Lab monitoring at intervals appropriate to your protocol. Functional medicine coaching between visits. Dosing adjustments based on response and tolerance.
Safety and side effects
GLP-1 medications have an extensive clinical trial record — the SURMOUNT and STEP trial series collectively represent tens of thousands of patient-years of data. That doesn't mean they're without considerations.
Common side effects (dose-related, typically temporary)
- Nausea — the most common side effect, especially during dose escalation. Usually improves significantly after 4–8 weeks
- Constipation — GLP-1 slows gastric motility; adequate fiber and hydration help
- Diarrhea — less common than constipation; tends to resolve quickly
- Reduced appetite / early satiety — the intended mechanism, but can feel uncomfortable initially
- Fatigue — common in early weeks; typically resolves as body adjusts
Important contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis (requires careful evaluation)
- Severe gastroparesis or other serious GI disorders
- Pregnancy or active plans to become pregnant
On muscle loss: Rapid weight loss — with or without GLP-1 medication — carries risk of losing lean muscle mass alongside fat. Dr. Morris's protocol specifically addresses this through protein optimization and resistance training guidance. Monitoring lean mass during treatment is a standard part of the program.
A thorough medical evaluation prior to prescribing is the primary safety mechanism. This is why Dr. Morris's protocol begins with a consultation and labs rather than a questionnaire and an instant prescription.
Pricing
Consultation fees and program pricing are listed on the main services page. Here's an overview of what to expect on the medication side:
- Name-brand Wegovy (semaglutide): List price ~$1,350/month. Covered by many commercial insurance plans for BMI-qualifying patients. Novo Nordisk offers savings programs for eligible patients.
- Name-brand Zepbound (tirzepatide): List price ~$1,060/month. Covered by many commercial insurance plans. Eli Lilly savings cards available.
- Compounded semaglutide / tirzepatide: Available through licensed compounding pharmacies at significantly lower cost where permitted by FDA and state regulations. Dr. Morris can discuss current availability and considerations.
- HSA/FSA: Both consultation fees and medication costs are generally eligible health expenses.
Insurance coverage for GLP-1 medications has expanded significantly — many commercial plans now cover Wegovy and Zepbound for BMI-qualifying patients with proper documentation. Dr. Morris's team assists with documentation for prior authorization when needed.